[Clinical significance of galactosyltransferase associated with tumor (GAT), a new tumor marker for ovarian cancer--with special reference to the discrimination between ovarian cancer and endometriosis]. 1994

S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
Dept. of Obstetrics and Gynecology, School of Medicine, Keio University.

We examined GAT, a newly developed tumor marker, in serum samples collected from 1,503 females in six institutions: 387 healthy females, 1,052 patients with gynecological diseases including 311 ovarian cancers, and 64 with nongynecological diseases. Based on the mean value + 2 SD for the healthy females, the cut-off value was set at 16 U/ml. The positive rate of GAT was 2.6% for the healthy females, 7.1% for patients with benign ovarian tumor, 5.6% for those with endometriosis, 47.9% for those with ovarian cancers, 9.3% for those with cervical cancer, and 13.3% for those with endometrial cancer. The false-positive rate of GAT for endometriosis was very low compared with that of the other markers such as CA 125, CA 602, CA 54/61, CA 72-4, STN, SLX examined in this study. The positive predictive value between ovarian cancer and endometriosis was the highest with GAT among the evaluated markers. In the cases in which the CA 125 (CA 602) value is relatively low, discrimination between ovarian cancer and endometriosis is difficult, because these cases include many patients with endometriosis. GAT showed the highest positive predictive value in such cases, so GAT proved to play a complementary role with CA 125 (CA 602). Combination assay with GAT and CA 54/61/CA 72-4/STN or SLX showed higher diagnostic efficiency between ovarian cancer and endometriosis. These results suggest the usefulness of GAT for discrimination between ovarian cancer and endometriosis.

UI MeSH Term Description Entries
D010049 Ovarian Diseases Pathological processes of the OVARY. Disease, Ovarian,Diseases, Ovarian,Ovarian Disease
D010051 Ovarian Neoplasms Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS. Cancer of Ovary,Ovarian Cancer,Cancer of the Ovary,Neoplasms, Ovarian,Ovary Cancer,Ovary Neoplasms,Cancer, Ovarian,Cancer, Ovary,Cancers, Ovarian,Cancers, Ovary,Neoplasm, Ovarian,Neoplasm, Ovary,Neoplasms, Ovary,Ovarian Cancers,Ovarian Neoplasm,Ovary Cancers,Ovary Neoplasm
D003937 Diagnosis, Differential Determination of which one of two or more diseases or conditions a patient is suffering from by systematically comparing and contrasting results of diagnostic measures. Diagnoses, Differential,Differential Diagnoses,Differential Diagnosis
D004715 Endometriosis A condition in which functional endometrial tissue is present outside the UTERUS. It is often confined to the PELVIS involving the OVARY, the ligaments, cul-de-sac, and the uterovesical peritoneum. Endometrioma,Endometriomas,Endometrioses
D005260 Female Females
D005700 Galactosyltransferases Enzymes that catalyze the transfer of galactose from a nucleoside diphosphate galactose to an acceptor molecule which is frequently another carbohydrate. EC 2.4.1.-. Galactosyltransferase
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014408 Biomarkers, Tumor Molecular products metabolized and secreted by neoplastic tissue and characterized biochemically in cells or BODY FLUIDS. They are indicators of tumor stage and grade as well as useful for monitoring responses to treatment and predicting recurrence. Many chemical groups are represented including HORMONES; ANTIGENS; amino and NUCLEIC ACIDS; ENZYMES; POLYAMINES; and specific CELL MEMBRANE PROTEINS and LIPIDS. Biochemical Tumor Marker,Cancer Biomarker,Carcinogen Markers,Markers, Tumor,Metabolite Markers, Neoplasm,Tumor Biomarker,Tumor Marker,Tumor Markers, Biochemical,Tumor Markers, Biological,Biochemical Tumor Markers,Biological Tumor Marker,Biological Tumor Markers,Biomarkers, Cancer,Marker, Biochemical Tumor,Marker, Biologic Tumor,Marker, Biological Tumor,Marker, Neoplasm Metabolite,Marker, Tumor Metabolite,Markers, Biochemical Tumor,Markers, Biological Tumor,Markers, Neoplasm Metabolite,Markers, Tumor Metabolite,Metabolite Markers, Tumor,Neoplasm Metabolite Markers,Tumor Markers, Biologic,Tumor Metabolite Marker,Biologic Tumor Marker,Biologic Tumor Markers,Biomarker, Cancer,Biomarker, Tumor,Cancer Biomarkers,Marker, Tumor,Markers, Biologic Tumor,Markers, Carcinogen,Metabolite Marker, Neoplasm,Metabolite Marker, Tumor,Neoplasm Metabolite Marker,Tumor Biomarkers,Tumor Marker, Biochemical,Tumor Marker, Biologic,Tumor Marker, Biological,Tumor Markers,Tumor Metabolite Markers
D015295 Antigens, Tumor-Associated, Carbohydrate Carbohydrate antigens expressed by malignant tissue. They are useful as tumor markers and are measured in the serum by means of a radioimmunoassay employing monoclonal antibodies. Antigens, Carbohydrate, Tumor-Associated,CA Antigens,Cancer-Associated Carbohydrate Antigens,Carbohydrate Antigens, Tumor-Associated,Tumor-Associated Carbohydrate Antigens,Antigen, Carcinoma-Associated,CA Antigen,CA(Oxford) Antigen,Carcinoma-Associated Antigen,Epitectin,Antigen, CA,Antigen, Carcinoma Associated,Antigens, CA,Antigens, Cancer-Associated Carbohydrate,Antigens, Tumor-Associated Carbohydrate,Cancer Associated Carbohydrate Antigens,Carbohydrate Antigens, Cancer-Associated,Carbohydrate Antigens, Tumor Associated,Carcinoma Associated Antigen,Tumor Associated Carbohydrate Antigens

Related Publications

S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
December 1999, Nihon rinsho. Japanese journal of clinical medicine,
S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
July 2010, Nihon rinsho. Japanese journal of clinical medicine,
S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
August 2005, Nihon rinsho. Japanese journal of clinical medicine,
S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
August 1992, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme,
S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
December 1971, Sanfujinka no jissai. Practice of gynecology and obstetrics,
S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
April 1989, Gan to kagaku ryoho. Cancer & chemotherapy,
S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
March 2024, Turkish journal of obstetrics and gynecology,
S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
January 2017, Gynecology and minimally invasive therapy,
S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
January 2011, Akusherstvo i ginekologiia,
S Nozawa, and Y Udagawa, and K Ito, and H Nishimura, and M Yakushiji, and M Shiota, and K Noda, and M Yajima, and H Ohkura, and M Murae
May 1987, Deutsche medizinische Wochenschrift (1946),
Copied contents to your clipboard!